Klas Gosta Wiman
Corporate Officer/Principal at Karolinska Institutet
Profile
Klas Gosta Wiman is the founder of Aprea Therapeutics, Inc. (founded in 2002) and Aprea Therapeutics AB (founded in 2003).
He is currently working as a Professor in the Oncology & Pathology Department at Karolinska Institutet.
Klas Gosta Wiman active positions
Companies | Position | Start |
---|---|---|
Karolinska Institutet | Corporate Officer/Principal | 2009-05-14 |
Former positions of Klas Gosta Wiman
Companies | Position | End |
---|---|---|
APREA THERAPEUTICS, INC. | Founder | - |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
APREA THERAPEUTICS, INC. | Health Technology |
Private companies | 1 |
---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
- Stock Market
- Insiders
- Klas Gosta Wiman